La vendita allo scoperto per Vistra dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Vistra. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Vistra (NYSE:VST) Azioni, Report sulle vendite allo scoperto

Vistra

Vistra Energy is one of the largest power producers and retail energy providers in the US. Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, solar, and energy storage assets. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.

Data center shutterstock_2525761293

Equities

News

Markets

Tech

Media

AMZN

ANET

AVGO

CARR

CRWV

CSCO

MSFT

NVDA

Visione ottimista sulle infrastrutture tech. L&#39;host di Mad Money cita big tech e indica settori ciclici pronti al rialzo con tregua dei dazi.

Jim Cramer controcorrente: &#34;Il boom AI non rallenta&#34;, ecco i titoli su cui punta

Hedge Funds

BBWI

CPAY

Scopri quali sono le 5 migliori azioni del portafoglio di Dan Loeb

Vistra Corp

Vasta Platform Limited - Class A Ordinary Shares

Vasta Platform Ltd

VISION TECHNOLOGY CORP by Vision Technology Corp.

Vision Technology Corp

Vast Renewables Limited - Ordinary Shares

Vast Renewables Ltd

VNV Global AB

Verastem Inc

VISTA OUTDOOR INC COM

Vestis Corp

RLJ Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>) lowers FY2025 FFO guidance from $1.46-$1.66 to $1.38-$1.58 vs $1.54 analyst estimate..

Guidance

RLJ Lodging Lowers FY2025 FFO Guidance from $1.46-$1.66 to $1.38-$1.58 vs $1.54 Est

ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) is looking for Q2 GAAP EPS of $0.45-$0.55 vs $0.45 analyst estimate. sees sales of $1.400 billion-$1.500 billion vs $1.42 billion analyst estimate.

ON Semiconductor Sees Q2 GAAP EPS $0.45-$0.55 vs $0.45 Est; Sees GAAP Sales $1.400B-$1.500B vs $1.42B Est

ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) is looking for Q2 Adj EPS of $0.48-$0.58 vs $0.52 analyst estimate. sees sales of $1.400 billion-$1.500 billion vs $1.42 billion analyst estimate.

ON Semiconductor Sees Q2 Adj EPS $0.48-$0.58 vs $0.52 Est; Sees Sales $1.400B-$1.500B vs $1.42B Est

Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 5.26 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $15.50 million which beat the analyst consensus estimate of $14.54 million by 6.56 percent. This is a 7.51 percent increase over sales of $14.41 million the same period last year.

Earnings

Earnings Beats

Exagen Q1 GAAP EPS $(0.20), Inline, Sales $15.50M Beat $14.54M Estimate

Legal

AMOD

Alpha Modus Subsidiary Reaches Settlement Agreement With Kroger In Patent Litigation

Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year
Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- <a href="https://rezolutebio.com/">Rezolute, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.&nbsp;

RZLT

Rezolute: FDA Grants Breakthrough Therapy Designation To Investigational Therapy, Ersodetug, For Treatment Of Hypoglycemia Caused By Tumor HI

RLJ Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $328.12 million which beat the analyst consensus estimate of $327.98 million by 0.04 percent. This is a 1.14 percent increase over sales of $324.41 million the same period last year.

RLJ Lodging Q1 EPS $(0.02) Beats $(0.04) Estimate, Sales $328.12M Beat $327.98M Estimate

ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.51 by 7.84 percent. This is a 49.07 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $1.45 billion which beat the analyst consensus estimate of $1.40 billion by 3.17 percent. This is a 22.38 percent decrease over sales of $1.86 billion the same period last year.

ON Semiconductor Q1 Adj. EPS $0.55 Beats $0.51 Estimate, Sales $1.45B Beat $1.40B Estimate

In the latest quarter, 7 analysts provided ratings for N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.46, a high estimate of $10.00, and a low estimate of $8.50. Highlighting a 19.01% decrease, the current average has fallen from the previous average price target of $11.68. 
<img src="https://www.benzinga.com/files/images/story/2025/1746446486_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of N-able among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$9.00</td>
<td>$8.75</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.50</td>
<td>$13.50</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$8.75</td>
<td>$11.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$16.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to N-able. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of N-able compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of N-able's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NABL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on N-able analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into N-able's Background</h2>
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
<h3>N-able: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: N-able displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.47%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: N-able's net margin excels beyond industry benchmarks, reaching 2.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): N-able's ROE excels beyond industry benchmarks, reaching 0.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): N-able's ROA stands out, surpassing industry averages. With an impressive ROA of 0.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.49.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

NABL

Breaking Down N-able: 7 Analysts Share Their Views

Throughout the last three months, 4 analysts have evaluated CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CareDx, revealing an average target of $29.0, a high estimate of $40.00, and a low estimate of $25.00. This current average has decreased by 7.2% from the previous average price target of $31.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1746446473_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of CareDx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CareDx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CareDx's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into CareDx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into CareDx's Background</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
<h3>A Deep Dive into CareDx's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining CareDx's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.54% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CareDx's net margin excels beyond industry benchmarks, reaching -12.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): CareDx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.73%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CareDx's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.11%, the company showcases efficient use of assets and strong financial health.
Debt Management: CareDx's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDNA

Analyst Expectations For CareDx's Future

Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) underwent analysis by 30 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $119.6, a high estimate of $140.00, and a low estimate of $100.00. This current average reflects an increase of 10.59% from the previous average price target of $108.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1746446454_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Okta. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Taz Koujalgi</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$119.00</td>
<td>-</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Brian Colley</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$127.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shaul Eyal</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$109.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$127.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Richard Davis</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Okta. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Okta compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Okta's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Okta's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OKTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Okta analyst ratings.</a>
<h2>Unveiling the Story Behind Okta</h2>
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
<h3>Financial Insights: Okta</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Okta showcased positive performance, achieving a revenue growth rate of 12.73% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Okta's net margin excels beyond industry benchmarks, reaching 3.37%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Okta's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.36%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Okta's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.25% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Okta's debt-to-equity ratio is below the industry average at 0.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OKTA

Analyst Expectations For Okta's Future

In the last three months, 10 analysts have published ratings on Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Onto Innovation, presenting an average target of $204.0, a high estimate of $250.00, and a low estimate of $135.00. A 16.39% drop is evident in the current average compared to the previous average price target of $244.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746446445_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Onto Innovation among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Edward Yang</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Edward Yang</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Onto Innovation. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Onto Innovation compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Onto Innovation's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Onto Innovation's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ONTO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Onto Innovation analyst ratings.</a>
<h2>Delving into Onto Innovation's Background</h2>
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
<h3>Onto Innovation: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Onto Innovation's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 20.6%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.5%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.55%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.33%, the company showcases effective utilization of assets.
Debt Management: Onto Innovation's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ONTO

Onto Innovation Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 -
- Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 -
- Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of&nbsp;NfL in Stage 2 patients at Month 24 -
- Continued favorable safety and tolerability profile with no treatment-related NfL spikes -
- PTC will host a conference call on May 5, 2025, at 8:00 am ET-
&nbsp;PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p&lt;0.0001) at Week 12 and favorable safety and tolerability. In addition, the 12-month data from the Stage 2 patients are consistent with the previously reported dose-dependent lowering of HTT protein and dose-dependent trends across clinical scales.
"These PIVOT-HD results confirm that PTC518 lowers Huntingtin protein and shows early signals of clinical benefit with a favorable safety profile," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. "In addition, at 24 months, we observed favorable dose-dependent trends on the cUHDRS and the TFC and SDMT subscales relative to natural history as well as dose-dependent lowering of neurofilament light chain protein. We look forward to discussions on the next development and regulatory steps including the potential for accelerated approval as we work to potentially bring the first disease-modifying therapy to those affected by Huntington's disease."

Biotech

General

PTCT

Ptc Therapeutics Announces Results From The Phase 2 Pivot-Hd Study of PTC518 In Stage 2 And Stage 3 Huntington's Disease Patients Study Met Its Primary Endpoint of Reduction in Blood Huntingtin Protein Levels At Week 12 And Favorable Safety and Tolerability

In the latest quarter, 7 analysts provided ratings for Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Asure Software, revealing an average target of $17.71, a high estimate of $20.00, and a low estimate of $13.00. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1746446434_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Asure Software's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Asure Software. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Asure Software compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Asure Software's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Asure Software's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ASUR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Asure Software analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Asure Software</h2>
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its HCM products majorly in the United States.
<h3>Unraveling the Financial Story of Asure Software</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Asure Software's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 10.12%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Asure Software's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Asure Software's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.21%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Asure Software's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Asure Software adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASUR

Expert Outlook: Asure Software Through The Eyes Of 7 Analysts

Across the recent three months, 4 analysts have shared their insights on Worthington Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $56.25, a high estimate of $67.00, and a low estimate of $44.00. This upward trend is apparent, with the current average reflecting a 14.21% increase from the previous average price target of $49.25.
<img src="https://www.benzinga.com/files/images/story/2025/1746446420_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Worthington Enterprises's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Susan Maklari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Martin Englert</td>
<td>Seaport Global</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$54.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Worthington Enterprises. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Worthington Enterprises compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Worthington Enterprises's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Worthington Enterprises's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WOR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Worthington Enterprises analyst ratings.</a>
<h2>About Worthington Enterprises</h2>
Worthington Enterprises Inc is a designer and manufacturer of products sold to consumers, through retail channels, in the tools, outdoor living and celebrations market categories as well as a wide array of specialized building products that serve customers in the residential and non-residential construction markets, including ceiling suspension systems and light gauge metal framing products, as well as wholly-owned and consolidated operations that produce pressurized containment solutions for heating, cooking and cooling applications, among others. It operates under two reportable operating segments: Consumer Products and Building Products. It derives majority of the revenue from Building Products segment.
<h3>Unraveling the Financial Story of Worthington Enterprises</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Worthington Enterprises's revenue growth over 3M faced difficulties. As of 28 February, 2025, the company experienced a decline of approximately -3.86%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.02%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Worthington Enterprises's ROE excels beyond industry benchmarks, reaching 4.29%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.38%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Worthington Enterprises Through The Eyes Of 4 Analysts

Leveraged exchange-traded funds have been experiencing a significant surge in investor interest lately. This is fueled by a confluence of factors ranging from anticipated interest rate cuts to the booming popularity of artificial intelligence and escalating geopolitical tensions.
What Happened: This growing appetite is driving substantial capital inflows into vehicles like ProShares UltraPro QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NASDAQ">TQQQ</a>), Direxion Daily Semiconductor Bull 3X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>), and Select STOXX Europe Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/EUAD#BATS">EUAD</a>).
&#8220;From interest rate speculation to momentum chasing, investors are rapidly reallocating capital toward vehicles that offer amplified exposure — and quicker returns,&#8221; said Eugenia Mykuliak, the founder and executive director of B2PRIME Group, a global financial services provider for institutional and professional clients.
Mykuliak stated the following factors that are responsible for investors&#8217; growing interest in such leveraged ETFs.
<ul>
<li>Anticipation of interest rate cuts is fueling leveraged ETF demand.</li>
<li>Leveraged ETFs as a tool to magnify gains in resilient markets.</li>
<li>Strategic hedging with leveraged ETFs amid tech strength.</li>
<li>Risk-on sentiment and momentum chasing are driving inflows.</li>
<li>Speculative nature and short-term focus in leveraged ETF trading.</li>
<li>AI boom attracting capital to leveraged ETFs with tech exposure.</li>
<li>Geopolitical tensions boosting the defense sector leveraged ETF interest.</li>
</ul>
Here&#8217;s a list of leveraged ETFs and how they have performed.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Leveraged ETFs</td>
<td>Last Five Days</td>
<td>YTD</td>
</tr>
<tr>
<td>ProShares UltraPro QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NASDAQ">TQQQ</a>)</td>
<td>10.14%</td>
<td>-24.42%</td>
</tr>
<tr>
<td>Direxion Daily Semiconductor Bull 3X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>)</td>
<td>9.47%</td>
<td>-51.97%</td>
</tr>
<tr>
<td>Select STOXX Europe Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/EUAD#BATS">EUAD</a>)</td>
<td>6.42%</td>
<td>50.78%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45187807/sp-500s-9-day-climb-not-a-recession-signal-argue-analysts-amid-conflicting-research-simply-wrong-lazy-analysis">S&amp;P 500&#8217;s 9-Day Climb Not A Recession Signal, Argue Analysts Amid Conflicting Research: &#8216;Simply Wrong/Lazy Analysis&#8217;</a>
Why It Matters: According to Mykuliak, the current market sentiment, characterized by a &#8220;risk-on behaviour,&#8221; is a significant driver.
She cautions about the speculative nature of some of these investments. &#8220;Short-term mindset is typically about speculation because positions are held for days, not months. So, chasing short-term profits is a speculative approach per se. The rising activity around options and other derivatives of these ETFs could also signal speculative positioning, rather than long-term strategic preparation.&#8221;
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.74% to $562.59, while the QQQ declined 0.89% to $484.50, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45188341/billionaire-mark-cuban-asks-if-small-businesses-be-ignored-after-trump-redirects-question-on-tariff-relief-for-little-businesses">Billionaire Mark Cuban Asks Should Small Businesses Be &#8216;Ignored&#8217; After Trump Redirects Question On Tariff Relief For &#8216;Little Businesses&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

Government

Macro Notification

Market Summary

Futures

Economics

ETFs

EUAD

SOXL

TQQQ

Leveraged ETFs Soar As Investors Seek 'Amplified Exposure And Quicker Returns:' Rate Bets, Tech Mania, And Geopolitical Shifts Drive Demand

Investment firm Bernstein expects corporate treasury allocations to drive approximately $330 billion into Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) over the next five years, fueled primarily by public companies adopting Strategy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45039399/strategy-buys-15355-bitcoin-for-142-billion-year-to-date-btc-yield-hits-137">capital deployment model.</a>
In a note published on Monday, Bernstein analysts outlined a base case in which listed corporates allocate around $205 billion to Bitcoin between 2025 and 2029, with Strategy contributing an additional $124 billion.
The firm said this projection hinges on continued replication of the MSTR playbook by companies with limited organic growth paths.
"Small, low-growth public companies with excess cash and limited prospects are likely to emulate MSTR's Bitcoin treasury strategy," the report stated. 
Bernstein identified around 2,000 such firms globally that meet its screening criteria, holding a combined $3.8 trillion in cash and equivalents. 
A 25% allocation from 20% of these firms alone could yield $190 billion in inflows.
MSTR, which has acquired approximately 554,000 BTC at a cost of $38 billion, continues to expand its exposure with an aggressive <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44563102/strategy-acquires-22048-more-bitcoin-for-1-92-billion-bringing-total-holdings-to-528185-btc">42:42 capital strategy</a>, raising $42 billion each from equity and debt markets by 2027.
According to Bernstein, the company has already completed about $27 billion of that plan.
The firm noted that public companies now collectively hold about 3.4% of the total Bitcoin supply, up sharply from 1.3% at the end of 2023. 
This concentration of long-term holders is contributing to declining exchange balances, further tightening circulating supply.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45165364/aptos-eyes-real-world-utility-beyond-nfts-and-defi-says-ecosystem-head-ash-pampati">Aptos Eyes Real-World Utility Beyond NFTs And DeFi, Says Ecosystem Head Ash Pampati</a>
Why It Matters: A favorable regulatory backdrop is another catalyst.
Bernstein cited the SEC's revocation of SAB 121, allowing banks to custody crypto assets without affecting their balance sheets and the new FASB rules that let corporates mark Bitcoin holdings to market, instead of only reporting impairments.
Still, Bernstein cautioned that not all companies attempting to replicate MSTR's model will succeed. 
"MSTR's edge lies in its financial innovation and track record of navigating multiple market cycles," the report stated. "Its ability to scale institutional-grade Bitcoin-linked instruments remains hard to match."
Even so, with growing capital market access, a declining BTC float, and a rising number of corporate imitators, Bernstein sees a structural supply squeeze taking shape, one that could reshape Bitcoin's long-term value dynamics.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45138065/uae-sets-global-benchmark-for-crypto-banking-integration-amina-banks-rohan-misra-says">UAE Sets Global Benchmark For Crypto-Banking Integration, Amina Bank&#8217;s Rohan Misra Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Corporations Will Pour $330 Billion Into Bitcoin By 2029: Bernstein

Peabody (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) announced today that it has notified Anglo American&nbsp;Plc of a Material Adverse Change (MAC) impacting Peabody's planned acquisition of steelmaking coal assets from Anglo. The MAC relates to issues involving the Moranbah North Mine, which remains inactive following what was described as a gas ignition event on March 31, 2025.
"While we have remained on track to complete the steelmaking coal acquisition from Anglo, the issues at Moranbah North have created significant uncertainty around the transaction," said Peabody President and Chief Executive Officer Jim Grech. "A substantial share of the acquisition value was associated with Moranbah North, yet there is no known timetable for resuming longwall production."
If the MAC is not resolved to Peabody's satisfaction in the limited timeframe specified under the companies' acquisition agreements, Peabody may elect to terminate the agreements.

Peabody Announces Notification Of Anglo American Regarding Material Adverse Change Impacting Planned Acquisition

Builds upon Firefly's recent acceptance into the NVIDIA Connect program
Marks next major step toward building a proprietary foundation model of the human brain
KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of Evoke Neuroscience, Inc. ("Evoke"), a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain health. The transaction marks <a href="https://www.globenewswire.com/Tracker?data=zUdRzwd07oiSxesoJlCzNapso1dPHHvs_TLIKVOZ5ClZywdxFcr4glbNtm6h_mE13MxcA4PfwkeGt-jP2mAFbtJIi_jSdNt3TlucVUmEW0KqsA2RbO-inf_3WdJIMYEIOI1D2CAPFg70PI_Lz3dm-rU8lIrplLG7IjoMH74pLjJsLhaUw25C0Y8PXluwMFvMoARP2N5VhFoeV_Vfr296WOp3hDAYXugiSNdXyZLKw3fZB4ihgf-sac1c57CKkFsa">another important step</a> toward Firefly building a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics ("BNA&#x2122;") technology.
Purchase terms include:
<ul>
<li>$6 million, to be paid 50% in cash and 50% in Firefly's common stock priced at $3.50 per share.</li>
<li>Eligibility for Evoke's investors to receive a $500,000 earn-out to be paid in cash upon Evoke's acquired business achieving at least $3 million in annualized revenues within the next three years.</li>
</ul>

AIFF

Firefly Neuroscience Acquires Evoke Neuroscience In $6M Cash-And-Stock Deal, Advancing Proprietary Brain Model Development

William Blair analyst Dylan Becker initiates coverage on Roper Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) with a Outperform rating.

Initiation

William Blair Initiates Coverage On Roper Technologies with Outperform Rating

Commodities

Offerings

Press Releases

Vistra Announces Private Offering of Senior Secured Notes

Vistra Prices Private Offering of $1.25 Billion of Senior Secured Notes

Dynegy and Homefield Energy Announce Recipients of the 2024 Energy Leadership Awards

Vistra Connects Two Utility-Scale Solar Facilities to Grid and Extends Operations of Baldwin Power Plant in Response to Reliability Concerns in MISO

Vistra Announces Expansion of its Board of Directors with the Appointment of Rob Walters

Vistra to Report Full Year and Fourth Quarter 2024 Results on Feb. 27, 2025

Dividends

Vistra Declares Dividend on Common Stock and Series A Preferred Stock

Vistra Reports Fourth Quarter and Full-Year 2024 Results

Vistra to Report First Quarter Results on May 7, 2025

Vistra Declares Dividend on Common Stock, Series B Preferred Stock and Series C Preferred Stock

AleAnna

Central Puerto S.A. American Depositary Shares (each represents ten Common Shares)

Comments

Vistra

Vendite allo scoperto

Vistra (NYSE:VST) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO